Clinical trial
Safety and Efficacy of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma: a Phase 2 Study
NCT05232552 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficacy of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma: a Phase 2 Study
- Lead sponsor
- Zhejiang Cancer Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- January 1, 2021
- Completion date
- December 31, 2024
- Enrollment
- 37 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.